Clinical Trials Directory

Trials / Completed

CompletedNCT04519541

RAMBAM 021: Safety and Initial Feasibility of the Neurolyser XR for the Treatment of Chronic Low Back Pain

Safety and Initial Feasibility of Using the Neurolyser XR Device for the Treatment of Axial Chronic Low Back Pain

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
10 (actual)
Sponsor
FUSMobile Inc. · Industry
Sex
All
Age
55 Years – 85 Years
Healthy volunteers
Not accepted

Summary

Single arm pilot study to evaluate the safety and initial feasibility of the Neurolyser XR, a high intensity focused ultrasound device, for non-invasive treatment of axial chronic low back pain

Detailed description

Study design: Prospective, single arm Timeline: six month enrollment period and 12 months follow-up period. Sites: The study will be conducted at five sites in Canada: McGill University, Toronto Western, Silver Medical Group, Precision Sport \& Spine, Kinetix Integrated Orthopaedic \& Regenerative Medicine Study population: Thirty adult patients diagnosed with facet related low back pain. Primary study objective: Safety and efficacy of the Neurolyser XR for the treatment of chronic low back pain secondary to zygapophyseal joint syndrome. Safety is measured by the incidence and severity of treatment related adverse events. Efficacy is measured by the changes in pain severity at the treatment area, using a numerical rating scale (NRS), of 0 to 10 between baseline and 6 months.

Conditions

Interventions

TypeNameDescription
DEVICENon-Invasive Thermal Ablation of the Medial Branch Nerves using the Neurolyser XRThermal ablation of the medial nerve branch using High Intensity Focused Ultrasound

Timeline

Start date
2021-02-03
Primary completion
2022-09-11
Completion
2023-01-31
First posted
2020-08-19
Last updated
2023-09-07

Locations

1 site across 1 country: Israel

Source: ClinicalTrials.gov record NCT04519541. Inclusion in this directory is not an endorsement.